Clinical Trials

Studies Currently Recruiting Participants



Principal Investigator: Mumtaz Zaman, MD, FCCP
Sponsor: Forest Laboratories
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD Identifier: NCT01966107
Purpose: The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations.


Principal Investigator: Philip Wexler, MD
Sponsor: AstraZeneca

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History Identifier: NCT02138916
Purpose: The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.


Principal Investigator: Mumtaz Zaman, MD, FCCP
Sponsor: GlaxoSmithKline

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Identifier: NCT02164513
Purpose: The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD



These Studies are Ongoing, but not Recruiting Participants


Principal Investigator: Philip Wexler, MD
Sponsor: Hoffmann-La Roche

An Observational Study in Patients With Asthma Initiating Treatment With Xolair (Omalizumab) Identifier:NCT01922037
Purpose: This observational study will evaluate the correlation of patient's characteristics with predictive markers of clinical outcome in patient with moderate to severe asthma initiating treatment with Xolair (omalizumab). Data will be collected for 48 weeks.



Principal Investigator: Mumtaz Zaman, MD, FCCP
Sponsor: Actelion

Collaborator: Canadian Heart Research Centre
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Identifier: NCT01389206
Purpose: This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.